News Reader.info

Access through your institution Buy or subscribe In the phase III LYM-3002 trial, patients with untreated stage II–IV mantle cell lymphoma were randomly assigned to receive either rituximab,

cyclophosphamide, doxorubicin, bortezomib, and prednisone (VR-CAP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). In an 82-month follow-up analysis of

140 patients in the VR-CAP group and 128 patients in the R-CHOP group, median overall survival was significantly longer in the VR-CAP group (90.7 months versus 55.7 months; _P_ = 0.001). The

toxicity profile of both regimens was considered manageable: discontinuation owing to treatment-related adverse events (AEs) occurred in 8% of patients in the VR-CAP group and 6% of the

R-CHOP group; 4% of patients in each group died owing to treatment-related AEs. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your

institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to this journal

Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices

may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support

REFERENCES ORIGINAL ARTICLE * Robak, T. et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin,

vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3

study. _Lancet Oncol._ https://doi.org/10.1016/S1470-2045(18)30685-5 (2018) Article  PubMed  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Nature Reviews

Clinical Oncology http://www.nature.com/nrclinonc Diana Romero Authors * Diana Romero View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING

AUTHOR Correspondence to Diana Romero. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Romero, D. Benefit with VR-CAP in mantle cell lymphoma. _Nat Rev

Clin Oncol_ 16, 6 (2019). https://doi.org/10.1038/s41571-018-0130-z Download citation * Published: 06 November 2018 * Issue Date: January 2019 * DOI:

https://doi.org/10.1038/s41571-018-0130-z SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative